Complete remission achieved in a case of both primary and recurrent adult acute myelogeneous leukemia by a novel nutritional therapy.
OBJECTIVE
The aim of this study was to determine the possible clinical benefit of molasses-based dietary compositions (designated as MSQ 13, MSQ 15, and MSQ 18) in a case of both primary and recurrent adult AML.


METHODS
The design was a single case study.


METHODS
The setting was in the home.


METHODS
The regime of dietary compositions initially was administered as follows: MSQ-13 1 tbsp t.i.d. for 1 mo, MSQ-15 2 tbsp t.i.d. for 3 mo. After recurrence, MSQ-18 was taken at 2 tbsp t.i.d. for 3 mo.


METHODS
Clinical improvement and regression of AML were the outcome measures.


CONCLUSIONS
Treatment with the MSQ dietary compositions resulted in disease regression and the reversal of clinical manifestations over two episodes of AML. Therefore, further studies are warranted to evaluate the utility of this approach for the clinical management of AML.
Grandics
Peter
P
A-D Research Foundation, Carlsbad, CA 92008, USA. pgrandics@earthlink.net
D000328:Adult; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000178:diet therapy* / Q000188:drug therapy; D008965:Molasses; D044623:Nutrition Therapy / Q000379:methods*; D012074:Remission Induction; D016896:Treatment Outcome